Recently, the Siltartoxatug Injection (trade name: 新替妥/Xintituo) of Zhuhai Trinomab Pharmaceutical Co., Ltd. is approved for marketing through the priority review and approval procedure by China NMPA. This product is indicated for emergency prophylaxis of tetanus in adults.

It is a recombinant anti-tetanus toxin monoclonal antibody, which provides passive immunity primarily by binding to the AB fragment of tetanus toxin. The marketing of this drug provides a new option for clinical medication.